Melanoma management is being redefined by emerging targeted and immune therapies. As the therapeutic options expand, Dr Jeffrey Weber and the team of specialists at New York University Langone Medical Center work to individualize therapy at each stage of disease, including appropriate management of local and regional disease, the choice of adjuvant therapy in high-risk patients, and the selection of first- and second-line therapies for recurrent disease. The NYU Langone team sorts through the complexity of issues and offers oncologists practical guidance in managing metastatic patients with a disease that was previously considered a death sentence.
Show More
Comments